The podcast features a roundtable discussion among chief editors from Life Science Connect, reflecting on the past year and forecasting trends for 2026. The conversation centers on the state of funding in biotech, with most editors noting a shift towards risk aversion and a challenging environment for early-stage research. A key surprise was the high turnover at the FDA, including the resignation of Peter Marks, which raised concerns about leadership and policy execution. Discussions also covered the increasing influence of China in biotech R&D, advancements in AI for drug discovery and manufacturing, and the growing importance of new approach methodologies (NAMs) in preclinical research. The editors also highlighted the need for better communication and customer service in the outsourcing space.
Sign in to continue reading, translating and more.
Continue
